RD-162 is a second-generation nonsteroidal antiandrogen (NSAA) which was developed for the treatment of prostate cancer but was never marketed.[1] It acts as a potent and selective silent antagonist of the androgen receptor (AR).[1] The drug is a diarylthiohydantoin derivative.[1] It is closely related to enzalutamide and apalutamide.[1] Both RD-162 and enzalutamide show 5- to 8-fold higher affinity for the AR than the first-generation NSAA bicalutamide, and only 2- to 3-fold lower affinity than dihydrotestosterone (DHT), the major endogenous ligand of the receptor in the prostate gland.[1]
 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| Drug class | Nonsteroidal antiandrogen |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C22H16F4N4O2S |
| Molar mass | 476.45 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
RD-162 and enzalutamide were developed together and were derived from the nonsteroidal androgen RU-59063, which itself was derived from the first-generation NSAA nilutamide.[2] RD-162 and enzalutamide were selected as the lead compounds from a group of over 200 compounds that were synthesized and assayed for antiandrogenic activity.[1] Enzalutamide was ultimately selected from the two for further clinical development and was eventually marketed.[1] RD-162 is also very closely related to apalutamide, with the two compounds differing only by the replacement of a single atom (a carbon atom in one of the phenyl rings of RD-162 swapped with a nitrogen atom in apalutamide). Apalutamide was approved for the treatment of prostate cancer in 2018.[3]
References
edit- ^ a b c d e f g Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL (2009). "Development of a second-generation antiandrogen for treatment of advanced prostate cancer". Science. 324 (5928): 787–90. Bibcode:2009Sci...324..787T. doi:10.1126/science.1168175. PMC 2981508. PMID 19359544.787-90&rft.date=2009&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981508#id-name=PMC&rft_id=info:pmid/19359544&rft_id=info:doi/10.1126/science.1168175&rft_id=info:bibcode/2009Sci...324..787T&rft.aulast=Tran&rft.aufirst=C&rft.au=Ouk, S&rft.au=Clegg, NJ&rft.au=Chen, Y&rft.au=Watson, PA&rft.au=Arora, V&rft.au=Wongvipat, J&rft.au=Smith-Jones, PM&rft.au=Yoo, D&rft.au=Kwon, A&rft.au=Wasielewska, T&rft.au=Welsbie, D&rft.au=Chen, CD&rft.au=Higano, CS&rft.au=Beer, TM&rft.au=Hung, DT&rft.au=Scher, HI&rft.au=Jung, ME&rft.au=Sawyers, CL&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981508&rfr_id=info:sid/en.wikipedia.org:RD-162" class="Z3988">
- ^ Liu B, Su L, Geng J, Liu J, Zhao G (2010). "Developments in nonsteroidal antiandrogens targeting the androgen receptor". ChemMedChem. 5 (10): 1651–61. doi:10.1002/cmdc.201000259. PMID 20853390. S2CID 23228778.1651-61&rft.date=2010&rft_id=https://api.semanticscholar.org/CorpusID:23228778#id-name=S2CID&rft_id=info:pmid/20853390&rft_id=info:doi/10.1002/cmdc.201000259&rft.aulast=Liu&rft.aufirst=B&rft.au=Su, L&rft.au=Geng, J&rft.au=Liu, J&rft.au=Zhao, G&rfr_id=info:sid/en.wikipedia.org:RD-162" class="Z3988">
- ^ "Apalutamide - Janssen Research and Development - AdisInsight".
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |